Drug Trial Radar · NCT00268697
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
Last checked: Nov 19, 2026Latest source record: May 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,267
Actual
Start
Oct 2005
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia
Conditions
- Hypercholesterolemia
Interventions
Lapaquistat acetateDrug
Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
Lapaquistat acetate and ezetimibeDrug
Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
EzetimibeDrug
Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in fasting plasma Low Density Lipoprotein cholesterolTime frame: Week 24 or Final Visit
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Tallinn, Estonia
Site not named
Tartu, Estonia
Site not named
Riga, Latvia
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Site not named
Saratov, Russia
Site not named
Smolensk, Russia
Site not named
Tyumen, Russia
Site not named
Kragujevac, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.